Graphite Bio co-founder debuts Treg cell therapy startup with $75M, aims to ‘trick’ immune system into resetting
17 Jan 2024
Cell TherapyImmunotherapy
Tr1x launched from stealth Wednesday with $75 million to tackle graft-versus-host disease in addition to inflammatory and autoimmune conditions.
The biotech was created by Maria Grazia Roncarolo, the Stanford Medicine scientist who co-founded Graphite Bio and Kamau Therapeutics. Bill Lis, who previously led Jasper Therapeutics and Portola Pharmaceuticals, is Tr1x’s CEO.
Roncarolo’s team was the first to discover a type of immune cell called type 1 regulatory T cells — or Tr1 cells — the namesake of the company.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.